Philip Morris urges TPSAC to recommend continued marketing of IQOS as MRTP

Experts from Philip Morris (PM) International presented evidence to the Tobacco Products Scientific Advisory Committee. The committee, comprised of independent scientific researchers, provides nonbinding recommendations to the U.S. Food and Drug Administration’s Center for Tobacco Products. The full-day meeting on October 7 was part of the FDA’s customary review of PMI’s request to continue marketing versions of its IQOS heated tobacco products in the U.S. as modified risk tobacco products, a necessary step while FDA completes its review of pending applications for IQOS ILUMA to reach and transition even more legal-age adults away from combustible cigarettes. “The evidence presented at this meeting, as also noted by the FDA, further supports the agency’s original conclusions that led the FDA to authorize the IQOS system as a modified risk tobacco product,” said Stacey Kennedy, PMI U.S. CEO. “We encourage the FDA to continue efforts to establish a timely scientific review process for smoke-free products-including for IQOS ILUMA, which has been pending FDA review for nearly two years and has globally shown even higher rates of legal-age adults fully switching from combustible cigarettes-that are a better choice for legal-age adults who would otherwise use traditional tobacco products, including combustible cigarettes.”